A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts

Oncotarget

Volumn 5, Issue 4, 2014, Pages 901-907

  Xie, Xiaoqi ^a   Bansal, Nitu ^a   Shaik, Tazeem ^a   Kerrigan, John E ^a   Minko, Tamara ^b   Garbuzenko, Olga ^b   Abali, Emine Ercikan ^c   Johnson Farley, Nadine ^a   Banerjee, Debabrata ^a   Scotto, Kathleen W ^a   Bertino, Joseph R ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Du 145 cells; Penetratin peptide; Prostate cancer

Indexed keywords

LIPOSOME; METHOTREXATE; PENETRATIN; TRANSCRIPTION FACTOR E2F; E2F1 PROTEIN, HUMAN; PEPTIDE; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG INHIBITION; ENCAPSULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN TARGETING; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; E2F1 TRANSCRIPTION FACTOR; HUMANS; MALE; MICE; MICE, NUDE; PEPTIDES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897387919     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1809     Document Type: Article

References (24)

1. Xie X, Kerrigan JE, Minko T, Garbuzenko O, Lee KC, Scarborough A, Abali EE,Budak-Alpdogan T, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR. Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small celllung cancer. Cancer Biol Ther. 2013; 8:742-51.
2. Bieda M, Xu X, Singer M, Green R Farnham) Unbiased location analysis of E2F-1 binding sites suggests a widespread role for E2F-1 in the human genome. Genome Res. 2006; 6:595-605.
3. Hallstrom TC, Mori S, Nevins JR. An E2F-1 gene expression program that determines the balance between proliferation and cell death. Cancer Cell 2008; 13:1311-22.
4. Kong LJ, Chang JT, Bild AH, Nevins JR. Compensation and specificity of function within the E2F family. Oncogene 2007;26:321-7.
5. Stevens C, La Thangue NB.The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst).) 2004; 3:1071-9.
6. Rabinovich A, Jin VX, Rabinovich R, Xu X, Farnham PJ. E2F in vivo binding specificity: comparison of consensus versus non-consensus binding sites. Genome Res 2008;18:1763-1777.
7. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81:323-30.
8. Classon M., Harlow E. The retinoblastoma tumor suppressor in development and cancer. Nat Rev Cancer 2002; 2: 910-7.
9. Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 2013;14:297-306.
10. Huang C-I., Liu D., Nakano J., Yokomise H., Ueno M., Kadota K and Wada H. E2F1 overexpression correlates with thymidylate synthase and survivin gene expression and tumor proliferation in non small cell lung cancer. Clin. Can Res. 2007;13. 6938-6946.
11. Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N, Kittas C, Papavassiliou AG. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol. 2002;198:142-56.
12. Kaelin WG, Jr. E2F-1 as a target: promoter driven suicide and small molecule modulators. Cancer Biology and Therapy 2003;2: SO48-S054.
13. Bertino JR, Banerjee D. E2F-1 as a drug target. Oncology Reviews 2010; 3:207-214.
14. Bashari D, Hacohen D, Ginsberg D. JNK activation is regulated by E2F and promotes E2F1-induced apoptosis. Cell Signal. 2011; 23:65-70.
15. Chou TC. Drug combination studies and their synergy quantification using theChou-Talalay method. Cancer Res. 2010 ; 70:440-6.
16. Sowers R, Toguchida J, Qin J, Meyers PA, Healey JH, Huvos A, Banerjee D, Bertino JR, Gorlick R. mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma. Mol Cancer Ther. 2003; 2:535-41.
17. Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E. Expression of the E2F family in human gastrointestinal carcinomas. Int J Cancer. 1999; 81:535-8.
18. Eymin B, Gazzeri S, Brambilla C, Brambilla E. Distinct pattern of E2F1 expression in human lung tumors: E2F1 is upregulated in small cell lung carcinoma. Oncogene. 2001; 20:1678-87.
19. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, Klein-Szanto AJ. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev. 2000; 4:395-401. PubMed PMID: 10794484.
20. Iwamoto M, Banerjee D, Menon LG, Jurkiewicz A, Rao PH, Kemeny NE, Fong Y, Jhanwar SC, Gorlick R, Bertino JR. Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification. Cancer Biol Ther. 2004; 5:395-9.
21. Nelson MA, Reynolds SH, Rao UN, Goulet AC, Feng Y, Beas A, Honchak B, Averill J, Lowry DT, Senft JR, Jefferson AM, Johnson RC, Sargent LM. Increased gene copy number of the transcription factor E2F1 in malignant melanoma. Cancer Biol Ther. 2006; 5:407-12
22. Alla V, Engelmann D, Niemetz A, Pahnke J, Schmidt A, Kunz M, Emmrich S, Steder M, Koczan D, Pützer BM. E2F1 in melanoma progression and metastasis. J Natl Cancer Inst. 2010; 102:127-33.
23. Ma Y, Kurtyka CA, Boyapalle S, Sung SS, Lawrence K, Guida W Cress WD.. A small molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res.2008; 68: 6292-6299.
24. Biswas Ak, Johnson DG.. Transcriptional and non-transcriptional functions of E2F-1 in response to DNA damage. Cancer Res. 2012; 72: 13-17.